Aurinia Pharmaceuticals Inc.AUPH
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · auriniapharma.com
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Key ratios
Operating cash flow growth
47.5%TTM
2025
205.6%
EPS growth
319.1%TTM
2025
5075.0%
FCF / Sales
55.0%TTM
2025
47.8%2024
18.8%2023
-19.5%
Net margin
97.7%TTM
2025
101.5%2024
2.5%2023
-44.5%
ROA
15.3%TTM
2025
11.2%2024
1.4%2023
-10.5%
ROE
61.4%TTM
2025
59.9%2024
1.5%2023
-19.9%
Revenue growth
21.0%TTM
2025
20.4%2024
34.0%2023
31.0%
Track AUPH in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer